MAPT and Alzheimer disease: The lack of evidence for significant co‐pathology in Aβ‐positive tau‐PET‐negative compared to tau‐PET‐positive AD patients could in part be explained by the heterogeneity of co‐pathology in the group, making it difficult to detect significant differences in this minority of AD patients.